eduKate Learning Manual
Science | Veterinary World
Ask the Haemostasis Question → Measure Clot Development in Whole Blood → Read Initiation, Growth, Strength and Lysis → Check Method and Sample → Compare With the Animal → Reassess

Veterinary Viscoelastic Coagulation Testing

Why Normal PT and aPTT Can Miss the Whole Clotting Picture

Wait, What? Blood Can Pass Two Familiar Clotting-Time Tests and Still Behave Abnormally as a Clot

A tube of plasma can tell us something important about how long selected coagulation pathways take to generate a fibrin signal. But a living clot is not made by plasma factors alone.

Platelets contribute. Fibrinogen contributes. Red cells influence the physical environment. Clot formation has a beginning, a growth phase, a final strength and a period in which the clot may later break down. A conventional clotting time deliberately observes only part of that story.

normal PT/aPTT ≠ every component of haemostasis normal ≠ bleeding or thrombosis risk fully understood.

Viscoelastic testing asks a different question: how does a whole-blood clot develop and change over time under this specific test system?

The Scientific Job

This page owns one Veterinary World job:

How do whole-blood viscoelastic tests such as TEG, ROTEM and newer point-of-care systems describe clot initiation, propagation, strength and lysis, and why must their results remain method-, sample- and context-specific?

Veterinary Coagulation Testing retains conventional plasma-based clotting tests, platelet evidence and the broader screening logic for bleeding. Veterinary Blood Smear retains cell morphology. This page owns the time-dependent mechanical behaviour of whole-blood clot formation and breakdown.

Quick Answer

Viscoelastic coagulation tests follow the developing mechanical properties of a whole-blood clot over time. Depending on the device and assay, they can provide information about how quickly clotting begins, how rapidly the clot strengthens, how firm it becomes and how it later loses strength. They complement conventional coagulation tests; they do not make every other haemostasis test obsolete.

The PROVETS evidence-based veterinary guidelines emphasise standardisation because thromboelastography and rotational thromboelastometry are sensitive to instrument, activator, collection technique, handling and local reference intervals. Results from different systems should not simply be treated as interchangeable numbers.

Explore PROVETS — Evidence-Based Guidelines for Veterinary Viscoelastic Assays →

Primary Entry — Conventional Clotting Times and Viscoelastic Tests Look Through Different Windows

Prothrombin time and activated partial thromboplastin time are valuable. They are designed to measure the time to fibrin formation under defined laboratory conditions in plasma. That makes them sensitive to particular coagulation-factor abnormalities and useful for specific diagnostic questions.

But they stop early in the physical life of the clot. They do not directly describe the later build-up of clot strength or the contribution of cellular components in whole blood.

Viscoelastic testing therefore does not “beat” PT or aPTT at the same job. It asks a broader mechanical question with its own limitations.

Part 1 — Think of the Trace as a Movie, Not a Single Finish Time

A conventional clotting time can be imagined as a stopwatch: how long until a defined endpoint appears?

A viscoelastic trace is more like a movie of changing clot mechanics. Different systems use different variable names, but broadly the trace can reflect:

initiation: how long before measurable clot formation begins;
propagation: how rapidly the clot develops;
strength: how firm the clot becomes;
lysis: how the clot loses strength over time.

The trace therefore contains several kinds of information that a single clotting-time endpoint cannot contain.

Part 2 — “Whole Blood” Matters Because Haemostasis Is a Team Event

Coagulation factors form only one layer of haemostasis. Platelets provide a cellular surface and contribute to clot strength. Fibrinogen is converted into fibrin. Red-cell concentration can influence viscoelastic measurements and clot architecture. Endothelial biology and blood flow matter in the living patient even though they are incompletely represented in an ex vivo cup or cartridge.

This is why the phrase “global haemostasis test” should be used cautiously. Viscoelastic testing integrates more components than plasma clotting times, but it still does not reproduce the intact blood vessel and living circulation.

broader laboratory model ≠ whole living haemostatic system.

Part 3 — A Short Initiation Time Does Not Automatically Mean the Animal Will Thrombose

A viscoelastic trace can appear relatively hypercoagulable under a defined protocol—for example, by forming or strengthening a clot faster than a reference population. That is evidence about the sample’s behaviour in the assay.

It is not a direct prophecy that the animal will form a clinical thrombus. Thrombosis depends on vessel-wall biology, blood flow, inflammation, disease, anticoagulant pathways and other factors beyond the test cartridge.

Likewise, a relatively hypocoagulable trace does not predict the exact site or timing of bleeding.

Part 4 — Clot Strength Is Not Produced by One Component

A weak clot can arise from several mechanisms: low fibrinogen, reduced platelet number or function, severe factor abnormalities, dilution and other disturbances. A strong clot can also have several explanations.

That means a viscoelastic strength variable is a composite signal. It tells the clinician that the mechanical endpoint differs; it does not automatically identify which component caused the difference.

Part 5 — Lysis Is Part of the Story, but Not Every Form of Fibrinolysis Is Easy to See

After a clot forms, fibrinolytic systems can break fibrin down. Viscoelastic traces can show loss of clot strength, and different systems report lysis with different variables.

However, the PROVETS guidance notes limitations in how standard assays detect some fibrinolytic states. A trace that does not show dramatic lysis should therefore not be translated into “fibrinolysis is definitely normal” without considering the assay and clinical setting.

Explore PROVETS — Definitions and Data Reporting →

Secondary Deepening — Preanalytical Control Is Part of the Measurement

Viscoelastic testing is unusually good at reminding us that laboratory values begin before the machine starts.

Blood-collection site, anticoagulant, tube filling, time before analysis, temperature, activation protocol and sample handling can change results. PROVETS therefore recommends standardised acquisition and handling for serial and inter-patient comparison.

Explore PROVETS — Sample Acquisition and Handling →

This connects directly to the Veterinary Preanalytical Error manual: a sophisticated instrument cannot repair a sample whose collection changed the phenomenon being measured.

Part 6 — TEG and ROTEM Are Not Two Names for One Interchangeable Number

Different viscoelastic analysers use different mechanics, reagents and reporting variables. Even when two systems seem to describe similar phases of clotting, their absolute values are not automatically transferable.

The PROVETS system-comparability review concluded that results from TEG and ROTEM should not simply be extrapolated from one machine to another and recommended system-specific, site-specific reference values under standardised conditions.

Explore PROVETS — System Comparability →

Part 7 — Activators Change the Assay

Some protocols use activators to initiate clot formation more consistently. Different activators can emphasise different parts of the coagulation process and reduce some variability, but the resulting traces are not directly interchangeable.

PROVETS found evidence that activated citrated assays can reduce inherent variability compared with simple recalcification, while also stressing that results from different activating agents should not be treated as equivalent.

Explore PROVETS — Assay Activation and Test Protocol →

Part 8 — Even the Sampling Site Can Matter

A 2026 Veterinary Clinical Pathology study compared several blood-sampling methods in healthy dogs using a point-of-care viscoelastic coagulometer. Results differed sufficiently between sampling methods that the authors recommended using the same sampling method and site for follow-up of an individual patient.

That is a powerful reminder: if the protocol changes, the apparent biology may change with it.

Explore 2026 Study — Sampling Method and Viscoelastic Results in Dogs →

JC Deepening — The Trace Is a Convolution of Biology and Measurement

A useful abstract model is:

observed trace = patient haemostatic state × sample conditions × instrument mechanics × reagent protocol × analytical variation.

The symbols are not literal multiplication. They remind us that the output contains several interacting sources of variation. If serial measurements are taken under inconsistent conditions, the clinician may mistake a method change for a patient change.

Part 9 — Biological Variation Sets a Floor on How Small a “Real Change” Can Be

Even healthy animals do not produce identical results every time. A 2026 study of a point-of-care viscoelastic coagulometer in healthy dogs quantified intra-individual, inter-individual and analytical variation across repeated measurements.

The general lesson is broader than one device: repeated testing has natural variation. A small numerical difference between two traces may not represent clinically meaningful biological movement.

Explore 2026 Study — Biological Variation of Viscoelastic Parameters in Healthy Dogs →

Part 10 — Haematocrit and Platelet Count Can Shape the Trace

Whole-blood viscoelastic measurements are affected by cellular composition. Recent veterinary work has reported relationships between haematocrit, platelet count and viscoelastic variables. That means a “hypercoagulable-looking” or “weak-clot” pattern can sometimes be influenced by the physical composition of the sample itself.

Interpretation therefore becomes stronger when the complete blood count, fibrinogen and conventional coagulation evidence are available rather than hidden behind a single colourful trace.

Part 11 — Viscoelastic Testing Is Most Useful When the Question Is Explicit

“Run a TEG” is not a scientific question. The useful question might be:

Is clot formation delayed in a bleeding patient despite inconclusive conventional tests?
Is clot strength unusually low or high under this validated protocol?
Is there evidence of substantial clot breakdown?
Has the whole-blood clot phenotype changed meaningfully on a comparable serial test?

The test becomes more interpretable when the intended decision is known before the trace arrives.

Part 12 — “Global” Does Not Mean “Final”

Viscoelastic testing is sometimes described as providing a global view of coagulation. The phrase is useful if it means “multiple phases of clot development in whole blood.” It becomes misleading if it means “complete prediction of bleeding and thrombosis in the living animal.”

The vessel wall, endothelium, regional blood flow, inflammatory state and many anticoagulant pathways are incompletely represented outside the body. A test can be broad without being omniscient.

How Do We Know?

The veterinary evidence base includes PROVETS systematic reviews and consensus guidance on instrument comparability, sample acquisition, activation, definitions and reporting, alongside device-specific reference-interval and biological-variation studies. The recurring finding is not merely that viscoelastic testing is useful. It is that standardisation is inseparable from usefulness.

Recent point-of-care studies reinforce this by showing that sampling method and ordinary biological variation can materially influence the observed trace.

Observation vs Inference

Observation: PT and aPTT are within the laboratory reference intervals while a validated viscoelastic assay shows unusually weak clot strength.
Inference: conventional initiation-time screening did not identify the same abnormality; platelet, fibrinogen, cellular and assay-specific contributors still need evaluation.
Observation: a trace appears relatively hypercoagulable compared with the local reference interval.
Inference: the sample formed a faster or stronger clot under that protocol; clinical thrombosis is not thereby proven.
Observation: two serial tests differ after the sampling method changed.
Inference: patient change and preanalytical change are confounded until method effects are considered.

Evidence Boundaries

normal PT/aPTT ≠ all haemostasis normal.
abnormal viscoelastic trace ≠ mechanism identified.
hypercoagulable trace ≠ clinical thrombosis guaranteed.
hypocoagulable trace ≠ bleeding site predicted.
TEG value ≠ ROTEM value interchangeable.
same device ≠ comparable result when protocol changes.
one serial change ≠ true biological change automatically.
whole-blood test ≠ complete living-vessel haemostasis.

Common Misconceptions

Misconception	Better model
Normal PT and aPTT mean clotting is normal.	They assess selected plasma clotting-time pathways, not every component or phase of haemostasis.
TEG, ROTEM and newer devices produce equivalent numbers.	Instrument, activator, protocol and reference intervals are system-specific.
A hypercoagulable trace proves thrombosis.	It describes ex vivo clot behaviour; thrombosis remains a whole-patient clinical event.
Any difference on a repeat test is disease progression.	Sampling, analytical and biological variation must be considered first.

Unfamiliar Transfer

Dog A has prolonged PT/aPTT and a weak viscoelastic clot. Dog B has normal PT/aPTT but reduced clot strength on a validated local assay. Dog C has a strongly hypercoagulable-looking trace but no clinical thrombus. Dog D has two very different serial traces obtained by different sampling methods.

A strong learner does not force all four into one diagnosis. The learner asks which phase of haemostasis each test observed, which method generated the trace, whether the protocol stayed constant and which whole-patient evidence is still missing.

Checkpoint Questions

Why can normal PT and aPTT coexist with an abnormal viscoelastic trace?
What four broad phases can a viscoelastic trace describe?
Why does whole blood add information beyond plasma?
Why does a hypercoagulable trace not prove thrombosis?
Why are TEG and ROTEM results not directly interchangeable?
How can an activator change the result?
Why does sampling method matter?
What does biological variation mean for serial testing?
Why should CBC and fibrinogen evidence remain visible?
Why is “global haemostasis” an imperfect phrase?

Answer key

PT/aPTT focus on selected plasma clot-initiation pathways, whereas viscoelastic testing samples broader whole-blood clot mechanics.
Initiation, propagation, clot strength and lysis.
Platelets and cellular composition contribute to clot mechanics.
Clinical thrombosis also depends on vessel wall, flow, disease and in-vivo regulatory pathways.
The instruments, reagents, mechanics and reference intervals differ.
Activation changes how coagulation begins and can change variability and measured values.
Collection site and technique can alter the specimen and therefore the trace.
Healthy individuals vary over time, so not every numerical difference is biologically meaningful.
Cell counts and fibrinogen can help explain a composite clot-strength signal.
The test is broad but does not reproduce the intact endothelium and circulation.

Edge Science — Portable Coagulation Traces Are Getting Easier; Interpretation Is Getting Harder

Newer cartridge-based and point-of-care viscoelastic devices can move coagulation assessment closer to the patient and reduce some operational barriers. That creates an opportunity for richer serial data in emergency, surgical and critical-care settings.

It also creates a calibration problem. More devices mean more protocols, more reference populations and more temptation to compare unlike numbers. Machine-learning systems may eventually classify trace phenotypes or detect subtle temporal patterns, but useful automation will need to preserve the device, activator, sample method, haematocrit, platelet context and local reference framework rather than hide them.

Veterinary World Direction Graph

Veterinary viscoelastic coagulation testing → bleeding/thrombosis question → whole-blood sample → standardised collection → device/activator protocol → clot initiation → propagation → strength → lysis → CBC/fibrinogen/conventional test context → clinical correlation → comparable serial reassessment.

Veterinary Coagulation Testing owns conventional plasma and platelet screening. Preanalytical Error owns specimen integrity. This page owns whole-blood time-dependent clot mechanics and their method-specific interpretation.

Research Sources and Further Reading

Educational boundary: Abnormal bleeding, suspected thrombosis and severe coagulation disorders can be emergencies. This manual explains laboratory reasoning and evidence limits only. It does not provide transfusion thresholds, anticoagulant selection, drug dosing or individual bleeding/thrombosis treatment instructions.

Teaching Guide for Parents, Tutors and Teachers

For the people who teach because somebody depends on them.

Use a simple building analogy. PT and aPTT ask roughly, “How long until construction begins under these test conditions?” A viscoelastic trace continues watching: “How quickly does the structure grow, how strong does it become, and does it later fall apart?”

define the haemostasis question → preserve the sample → know the machine and protocol → read the phase of clotting → compare with other evidence → watch comparable change over time.

The mastery target is a learner who understands that a more complex test is not automatically a more final answer. Its value comes from knowing exactly which extra part of reality it observes—and exactly which parts remain outside the trace.

eduKate Singapore

eduKate Learning Manual: Veterinary Viscoelastic Coagulation Testing | Why Normal PT and aPTT Can Miss the Whole Clotting Picture